Abstract
Purpose. CL 284,846 (CL846) is an investigational non-benzodiazepine agent with hypnotic, anxiolytic, myorelaxant and anticonvulsant properties. This study assessed the pharmacokinetics and anticonvulsant action of CL846 in female Sprague-Dawley rats.
Methods. CL846 pharmacokinetics were examined after either an iv bolus dose (2.5 mg/kg) or a 6-hr infusion (0.4 mg/kg/hr). CL846 pharmacodynamics were evaluated with a pentylenetetrazol (PTZ) infusion 5 min after a CL846 in bolus dose (0 to 10 mg/kg). CL846 and the derived metabolite CL 284,859 (CL859) concentrations in serum and brain tissue were determined by HPLC with fluorescence detection.
Results. Both the steady-state volume of distribution (1636 ± 162 and 1804 ± 293 ml/kg, after bolus and infusion administration, respectively) and systemic clearance (19.1 ± 7.1 and 22.2 ± 4.3 ml/min/kg for bolus and infusion administration, respectively) were high. No differences in pharmacokinetic parameters were noted between the two modes of administration. The relationship between anticonvulsant effect and brain/serum concentrations was well described by an Emax model. CL846 was as effective as triazolam in antagonizing PTZ-induced seizures.
Conclusions. Under the conditions of the present study, CL846 pharmacokinetics were linear and stationary. Further evaluation of the anticonvulsant properties of CL846 is warranted, including the potential development of tolerance, which is well known for benzodiazepines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
E. O. Bixler, A. Kales, C. R. Soldatos, J. D. Kales, and S. Healey. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am. J. Psychiatry 136:1257–1262 (1979).
D. E. Ford and D. B. Kamerow. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 262:1479–1484 (1989).
T. W. Rall. Hypnotics and sedatives: ethanol, In A. Gilman Goodman, T. W. Rall, A. S. Nies, and P. Taylor (eds.), The Pharmacological Basis of Therapeutics, Pergamon Press, New York, 1990, pp. 345–382.
T. W. Rall and L. S. Schleifer. Drugs effective in the therapy of epilepsies, In A. Gilman Goodman, T. W. Rall, A. S. Nies, and P. Taylor (eds.), The Pharmacological Basis of Therapeutics, Pergamon Press, New York, 1990, pp. 436–462.
H. J. Kupferberg. Preclinical drug development in the antiepileptic drug development program: a cooperative effort of government and industry, in B. S. Meldrum and M. Williams (eds.), Current and Future Trends in Anticonvulsant, Anxiety and Stroke Therapy, Wiley-Liss, New York, 1990, pp. 113–130.
R. J. Porter. Conclusion, In G. Bartholini, L. Bossi, K. G. Lloyd, and P. L. Morselli (eds.), Epilepsy and GABA Receptor Agonists: Basic and Therapeutic Research, Raven Press, New York, 1985, pp. 449–452.
J. Gaudreault, F. Varin, and G. M. Pollack. Pharmacodynamics of triazolam (TZ): anticonvulsant action and tolerance development. Pharm. Res. 9:S-358 (1992).
B. Beer, J. R. Ieni, W. Wen-Hui, D. Clody, P. Amorusi, J. Rose, T. Mant, J. Gaudreault, A. Cato, and W. Stern. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J. Clin. Pharmacol. 34:335–344 (1994).
M. Gibaldi and D. Perrier. Noncompartmental analysis based on statistical moment, In M. Gilbaldi and D. Perrier (eds.), Pharmacokinetics, Marcel Dekker, New York, 1982, pp. 409–417.
G. A. Kyerematen, G. F. Owens, B. Chattopadhyay, J. D. deBethizy, and E. S. Vessel. Sexual dimorphism of nicotine metabolism and distribution in rats. Studies in vivo and in vitro. Drug. Metab. Dispos. 16:823–828 (1988).
M. Sakashita, Y. Mizuki, T. Hashizume, T. Yamaguchi, H, Miyazaki, and Y. Sekine. Pharmacokinetics of the gastrokinetic agent mosapride citrate after intravenous and oral administration in rats. Arzneim. Forsch. 43:859–863 (1993).
Y. Tanaka, Y. Deguchi, I. Ishii, and T. Terai. Sex differences in excretion of zenarestat in rat. Xenobiotica 21:1119–1125 (1991).
I. Chaudhary, W. DeMaio, R. G. Kelly, G. Morton, D. Cosulich, and G. Nicolau. In-vitro and in-vivo metabolism of CL 284,846, a novel non-benzodiazepine sedative/hypnotic in humans. Pharm. Res. 10:S-331 (1993).
M. Wirth, I. Chaudhary, D. Cosulich, and G. Nicolau. In-vitro metabolism of CL 284-486, a novel non-benzodiazepine sedative/hypnotic, in human and monkey liver preparations. Pharm. Res. 10:S-311 (1993).
C. Bellantuono, G. Reggi, G. Tognoni, and S. Garattini. Benzodiazepines: clinical pharmacology and therapeutic use. Drugs 19:195–219 (1980).
K. R. Lees, A. W. Kelman, J. L. Reid, and B. Whiting. Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. J. Pharmacokinet. Biopharm. 17:529–550 (1989).
J. Dingemanse, F. A. E. Sollie, D. D. Breimer, and M. Danhof. Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. J. Pharmacokinet. Biopharm. 16:203–228 (1988).
G. M. Pollack and D. D. Shen. A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. J. Pharmacol. Meth. 13:135–146 (1985).
J. Dingemanse, J. B. M. M. Van Bree, and M. Danhof. Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. J. Pharmacol. Exp. Ther. 249:601–608 (1989).
P. D. Kroboth, R. B. Smith, T. Rosanske, J. M. Hamilton, J. W. McAuley, F. J. Kroboth, and R. P. Juhl. Triazolam route of administration studies I. Pharmacokinetics. Pharm. Res. 3:110s (1986).
J. R. M. Haigh and M. Feely. Tolerance to the anticonvulsant effect of benzodiazepines. Trends Pharmacol. Sci. 9:361–366 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gaudreault, J., Varin, F. & Pollack, G.M. Pharmacokinetics and Anticonvulsant Effect of a New Hypnotic, CL 284,846, in Rats. Pharm Res 12, 1592–1597 (1995). https://doi.org/10.1023/A:1016224629614
Issue Date:
DOI: https://doi.org/10.1023/A:1016224629614